Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$1.18 USD
-0.03 (-2.48%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.19 +0.01 (0.85%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PLX 1.18 -0.03(-2.48%)
Will PLX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for PLX
Analysts Offer Insights on NA Companies: PLUXEE N.V. (PLX) and Brazilian Rare Earths Ltd. (ASX: AU:BRE)
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
Protalix BioTherapeutics GAAP EPS of $0.09 misses by $0.01, revenue of $65.49M beats by $1.54M
Earnings Scheduled For March 14, 2024